Clinical Trial: Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07102979) titled 'Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response' on July 29.

Brief Summary: The goal of this clinical trial is to learn whether simvastatin alone or in combination with ursodeoxycholic acid (UDCA) can reduce liver fibrosis, inflammation, and gut microbiota imbalance in patients with liver cirrhosis who have achieved viral eradication after hepatitis C or inactive hepatitis B.

The main questions the study aims to answer are:

Can simvastatin or UDCA reduce biomarkers of liver fibrosis and chronic inflammation?

Do these treatments imp...